Drug intelligence / Profile preview

zinc histidine hydrate

Development stage: Unknown
Lead developer: Nobelpharma
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

NPC-25 is a pharmaceutical formulation of zinc histidine hydrate developed for the treatment of hypozincemia. It is an orally administered drug designed to restore and maintain normal serum zinc levels in patients with low blood zinc (hypozincemia). The mechanism of action involves providing bioavailable zinc, which is essential for numerous enzymatic and metabolic processes in the body. NPC-25 has been evaluated in clinical trials for its efficacy and safety compared to other oral zinc supplements, such as NOBELZIN, demonstrating its ability to maintain target serum zinc concentrations over time[2][4][5]. The drug was developed by Nobelpharma.

Other names: zinc histizine hydrate

Beyond the preview

Go deeper on zinc histidine hydrate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on zinc histidine hydrate.

Explore the full profile